Lowest Price Guaranteed
Slides
267
Last Updated
July 2026
View Count
9579
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. mRNA Therapeutics
6.2.1. Advantages of mRNA Therapeutics
6.2.2. Key Applications of mRNA Therapeutics
6.3. mRNA Therapeutics
6.3.1. Advantages of mRNA Therapeutics
6.3.2. Key Applications of mRNA Therapeutics
6.4. mRNA Delivery Routes
6.5. mRNA Delivery Strategies
6.6. Key Challenges Associated with mRNA Therapeutics
6.7. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. mRNA Therapeutics: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Drug Candidate
7.2.3. Analysis by Type of Program
7.2.4. Analysis by Type of Delivery System
7.2.5. Analysis by Type of Molecule Encoded
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Therapeutic Area
7.3. mRNA Therapeutics: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Developers: Analysis by Number of Drugs Developed
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. mRNA Therapeutics: Product Competitiveness Analysis
8.4.1. mRNA Therapeutics Developed by Players based in North America
8.4.2. mRNA Therapeutics Developed by Players based in Europe
8.4.3. mRNA Therapeutics Developed by Players based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES: mRNA THERAPEUTICS DEVELOPERS BASED IN NORTH AMERICA
9.1. Chapter Overview
9.2. Leading Developers in mRNA Therapeutics Market based in North America
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. mRNA Therapeutics Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.2.2. Immorna
9.2.2.1. Company Overview
9.2.2.2. mRNA Therapeutics Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Moderna
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. mRNA Therapeutics Portfolio
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Providence Therapeutics
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. mRNA Therapeutics Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.2.5. Innovac Therapeutics
9.2.5.1. Company Overview
9.2.5.2. mRNA Therapeutics Portfolio
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Kernal Biologics
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. mRNA Therapeutics Portfolio
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Recode Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. mRNA Therapeutics Portfolio
9.2.7.4. Recent Developments and Future Outlook
9.2.8. Rejuvenation Technologies
9.2.8.1. Company Overview
9.2.8.2. Financial Information
9.2.8.3. mRNA Therapeutics Portfolio
9.2.8.4. Recent Developments and Future Outlook
9.2.9. RNAimmune
9.2.9.1. Company Overview
9.2.9.2. Financial Information
9.2.9.3. mRNA Therapeutics Portfolio
9.2.9.4. Recent Developments and Future Outlook
9.2.10. Turn Biotechnologies
9.2.10.1. Company Overview
9.2.10.2. Financial Information
9.2.10.3. mRNA Therapeutics Portfolio
9.2.10.4. Recent Developments and Future Outlook
9.2.11. Strand Therapeutics
9.2.11.1. Company Overview
9.2.11.2. Financial Information
9.2.11.3. mRNA Therapeutics Portfolio
9.2.11.4. Recent Developments and Future Outlook
10. COMPANY PROFILES: mRNA THERAPEUTICS DEVELOPERS BASED IN EUROPE
10.1. Chapter Overview
10.2. Leading Developers in mRNA Therapeutics Market based in North America
10.2.1. BioNTech
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. mRNA Therapeutics Portfolio
10.2.1.4. Recent Developments and Future Outlook
10.2.2. CureVac
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. mRNA Therapeutics Portfolio
10.2.2.4. Recent Developments and Future Outlook
10.2.3. Ethris
10.2.3.1. Company Overview
10.2.3.2. mRNA Therapeutics Portfolio
10.2.3.3. Recent Developments and Future Outlook
11. COMPANY PROFILES: mRNA THERAPEUTICS DEVELOPERS BASED IN ASIA-PACIFIC
11.1. Chapter Overview
11.2. Leading Developers in mRNA Therapeutics Market based in North America
11.2.1. Suzhou Abogen Biosciences
11.2.1.1. Company Overview
11.2.1.2. mRNA Therapeutics Portfolio
11.2.1.3. Recent Developments and Future Outlook
11.2.2. Gennova Biopharmaceuticals
11.2.2.1. Company Overview
11.2.2.2. Financial Information
11.2.2.3. mRNA Therapeutics Portfolio
11.2.2.4. Recent Developments and Future Outlook
11.2.3. RNACure
11.2.3.1. Company Overview
11.2.3.2. mRNA Therapeutics Portfolio
11.2.3.3. Recent Developments and Future Outlook
11.2.4. Walvax
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. mRNA Therapeutics Portfolio
11.2.4.4. Recent Developments and Future Outlook
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Therapeutics Market: Big Player Initiatives
12.3.1. Analysis by Year of Initiative
12.3.2. Analysis by Type of Initiative
12.3.3. Analysis by Year and Type of Initiative
12.3.4. Analysis by Type of Partnership
12.3.5. Analysis by Type of Expansion
12.3.6. Analysis by Year of Initiative and Company
12.3.7. Big Pharma Players: Analysis by Number of Initiatives
12.4. Benchmarking Analysis: Big Pharma Players
12.4.1. Spider Web Analysis: Bayer
12.4.2. Spider Web Analysis: Pfizer
12.4.3. Spider Web Analysis: Sanofi
12.5. Concluding Remarks
13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Start-ups focused on mRNA Therapeutics
13.3. Benchmarking of Start-ups
13.4. Startup-Health Indexing
13.4.1. Analysis by Location of Headquarters
13.4.2. Analysis by Company Strength
13.4.3. Analysis by Pipeline Maturity
13.4.4. Analysis by Pipeline Strength
13.4.5. Analysis by Financial Support
13.4.6. Analysis by Investor Strength
13.4.7. Analysis by Partnership Activity
13.4.8. Start-ups Health Indexing: Roots Analysis Perspective
14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. mRNA Therapeutics: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
14.3.3. Analysis by Trial Phase
14.3.4. Analysis of Number of Patients Enrolled by Trial Phase
14.3.5. Analysis by Trial Status
14.3.6. Analysis by Trial Registration Year and Trial Status
14.3.7. Analysis by Patient Gender
14.3.8. Analysis by Study Design
14.3.8.1. Analysis by Type of Allocation
14.3.8.2. Analysis by Type of Intervention Model
14.3.8.3. Analysis by Type of Masking
14.3.8.4. Analysis by Trial Purpose
14.3.9. Analysis by Type of Sponsor / Collaborator
14.3.10. Analysis by Geography
14.3.10.1. Analysis of Clinical Trials by Geography
14.3.10.2. Analysis of Clinical Trials by Geography and Trial Status
14.3.10.3. Analysis of Patients Enrolled by Geography and Trial Status
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. mRNA Therapeutics Market: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Therapeutic Area
15.3.5. Most Active Players: Analysis by Number of Partnerships
15.3.6. Analysis by Geography
15.3.6.1. Intercontinental and Intracontinental Agreements
15.3.6.2. Local and International Agreements
16. FUNDING AND INVESTMENTS
16.1. Chapter Overview
16.2. Funding Models
16.3. mRNA Therapeutics Market: Funding and Investment Analysis
16.3.1. Analysis by Year of Funding
16.3.1.1. Cumulative Year-wise Trend of Funding Instances
16.3.1.2. Cumulative Year-wise Trend of Amount Invested
16.3.2. Analysis by Type of Funding
16.3.2.1. Analysis of Funding Instances
16.3.2.2. Analysis of Amount Invested
16.3.3. Analysis by Year and Type of Funding
16.3.4. Analysis by Amount Raised by Year and Type of Funding
16.3.5. Analysis by Therapeutic Area
16.3.6. Most Active Players: Analysis by Number of Funding Instances
16.3.7. Most Active Players: Analysis by Amount Raised
16.3.8. Analysis by Geography
16.3.9. Most Active Players: Analysis by Number of Funding Instances
16.3.10. Most Active Players: Analysis by Amount Invested
16.4. Summary of Funding and Investments
17. PATENT ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. mRNA Therapeutics: Patent Analysis
17.3.1. Analysis by Type of Patent
17.3.2. Analysis by Patent Publication Year
17.3.3. Analysis by Type of Patent and Publication Year
17.3.4. Analysis by Patent Application Year
17.3.5. Analysis by Patent Jurisdiction
17.3.6. Analysis by CPC Symbols
17.3.7. Analysis by Type of Applicant
17.3.8. Leading Industry Players: Analysis by Number of Patents
17.3.9. Leading Non-Industry Players: Analysis by Number of Patents
17.3.10. Leading Inventors: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
17.4.1. Analysis of Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations
18. FDA APPROVAL STRATEGIES
18.1. Chapter Overview
18.2. Methodology
18.3. Key Parameters
18.4. General Reasons for Failure of Trials Focused on mRNA Therapeutics
18.5. Benchmarking Analysis: Distribution of Key Strategies by mRNA Therapeutics
19. OUTSOURCING: GO / NO-GO FRAMEWORK
19.1. Chapter Overview
19.2. Outsourcing: Go / No-Go Framework
19.3. mRNA Therapeutics Outsourcing: Go / No-Go Framework
19.3.1. Key Parameters and Assumptions
19.3.2. Methodology
19.3.3. Results and Interpretations
19.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
19.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
19.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies
20. MARKET IMPACT ANALYSIS
20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion
21. GLOBAL mRNA THERAPEUTICS MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global mRNA Therapeutics Market, Forecasted Estimates (Till 2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations
22. mRNA THERAPEUTICS MARKET, BY TARGET INDICATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. mRNA Therapeutics Market: Distribution by Target Indication
22.3.1. mRNA Therapeutics Market for Non-Small Cell Lung Cancer, Forecasted Estimates (Till 2035)
22.3.2. mRNA Therapeutics Market for Melanoma, Forecasted Estimates (Till 2035)
22.3.3. mRNA Therapeutics Market for Muscle-Invasive Urothelial Carcinoma, Forecasted Estimates (Till 2035)
22.3.4. mRNA Therapeutics Market for Propionic Acidemia, Forecasted Estimates (Till 2035)
22.3.5. mRNA Therapeutics Market for Cystic Fibrosis, Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. mRNA THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. mRNA Therapeutics Market: Distribution by Geographical Regions
23.3.1. mRNA Therapeutics Market in North America, Forecasted Estimates (Till 2035)
23.3.1.1. mRNA Therapeutics Market in the US, Forecasted Estimates (Till 2035)
23.3.1.2. mRNA Therapeutics Market in Canada, Forecasted Estimates (Till 2035)
23.3.2. mRNA Therapeutics Market in Europe, Forecasted Estimates (Till 2035)
23.3.2.1. mRNA Therapeutics Market in the Germany, Forecasted Estimates (Till 2035)
23.3.2.2. mRNA Therapeutics Market in France, Forecasted Estimates (Till 2035)
23.3.2.3. mRNA Therapeutics Market in Italy, Forecasted Estimates (Till 2035)
23.3.2.4. mRNA Therapeutics Market in UK, Forecasted Estimates (Till 2035)
23.3.2.5. mRNA Therapeutics Market in Spain, Forecasted Estimates (Till 2035)
23.3.2.6. mRNA Therapeutics Market in Rest of Europe, Forecasted Estimates (Till 2035)
23.3.3. mRNA Therapeutics Market in Aisa-Pacific, Forecasted Estimates (Till 2035)
23.3.3.1. mRNA Therapeutics Market in China, Forecasted Estimates (Till 2035)
23.3.3.2. mRNA Therapeutics Market in Japan, Forecasted Estimates (Till 2035)
23.3.3.3. mRNA Therapeutics Market in Australia, Forecasted Estimates (Till 2035)
23.3.3.4. mRNA Therapeutics Market in South Korea, Forecasted Estimates (Till 2035)
23.4. mRNA Therapeutics Market, By Geographical Regions: Market Dynamics Assessment
23.4.1. Penetration Growth (P-G) Matrix
23.4.2. Market Movement Analysis
23.5. Data Triangulation and Validation
24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
24.1. mRNA Therapeutics Market in North America: Distribution by Target Disease Indication
24.1.1. mRNA Therapeutics Market in North America for Non-Small Cell Lung Cancer, Forecasted Estimates (Till 2035)
24.1.2. mRNA Therapeutics Market in North America for Melanoma, Forecasted Estimates (Till 2035)
24.1.3. mRNA Therapeutics Market in North America for Muscle-Invasive Urothelial Carcinoma, Forecasted Estimates (Till 2035)
24.1.4. mRNA Therapeutics Market in North America for Propionic Acidemia, Forecasted Estimates (Till 2035)
24.1.5. mRNA Therapeutics Market in North America for Cystic Fibrosis, Forecasted Estimates (Till 2035)
25. MARKET OPPORTUNITY ANALYSIS: EUROPE
25.1. mRNA Therapeutics Market in Europe: Distribution by Target Disease Indication
25.1.1. mRNA Therapeutics Market in Europe for Non-Small Cell Lung Cancer, Forecasted Estimates (Till 2035)
25.1.2. mRNA Therapeutics Market in Europe for Melanoma, Forecasted Estimates (Till 2035)
25.1.3. mRNA Therapeutics Market in Europe for Muscle-Invasive Urothelial Carcinoma, Forecasted Estimates (Till 2035)
25.1.4. mRNA Therapeutics Market in Europe for Propionic Acidemia, Forecasted Estimates (Till 2035)
25.1.5. mRNA Therapeutics Market in Europe for Cystic Fibrosis, Forecasted Estimates (Till 2035)
26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
26.1. mRNA Therapeutics Market in Asia-Pacific: Distribution by Target Disease Indication
26.1.1. mRNA Therapeutics Market in Asia-Pacific for Non-Small Cell Lung Cancer, Forecasted Estimates (Till 2035)
26.1.2. mRNA Therapeutics Market in Asia-Pacific for Melanoma, Forecasted Estimates (Till 2035)
26.1.3. mRNA Therapeutics Market in Asia-Pacific for Muscle-Invasive Urothelial Carcinoma, Forecasted Estimates (Till 2035)
26.1.4. mRNA Therapeutics Market in Asia-Pacific for Propionic Acidemia, Forecasted Estimates (Till 2035)
26.1.5. mRNA Therapeutics Market in Asia-Pacific for Cystic Fibrosis, Forecasted Estimates (Till 2035)
27. CONCLUDING REMARKS
28. EXECUTIVE INSIGHTS
28.1. Chapter Overview
28.2. Company A
28.2.1. Company Snapshot
28.2.2. Interview Transcript: Business Development Manager
28.3. Company B
28.3.1. Company Snapshot
28.3.2. Interview Transcript: Senior Director, Business Development
28.4. Company C
28.4.1. Company Snapshot
28.4.2. Interview Transcript: Team Leader
28.5. Company D
28.5.1. Company Snapshot
28.5.2. Interview Transcript: Director of Advanced Drug Delivery
28.6. Company E
28.6.1. Company Snapshot
28.6.2. Interview Transcript: Deputy Director
28.7. Company F
28.7.1. Company Snapshot
28.7.2. Interview Transcript: Co-founder and Chief Executive Officer
28.8. Company G
28.8.1. Company Snapshot
28.8.2. Interview Transcript: Co-founder
28.9. Company H
28.9.1. Company Snapshot
28.9.2. Interview Transcript: Chief Executive Officer
28.10. Company I
28.10.1. Company Snapshot
28.10.2. Interview Transcript: Chief Executive Officer
28.11. Company J
28.11.1. Company Snapshot
28.11.2. Interview Transcript: Chief Executive Officer
28.12. Company K
28.12.1. Company Snapshot
28.12.2. Interview Transcript: Chief Executive Officer
28.13. Company L
28.13.1. Company Snapshot
28.13.2. Interview Transcript: President
28.14. Company M
28.14.1. Company Snapshot
28.14.2. Interview Transcript: Medical Professional
29. APPENDIX 1: TABULATED DATA
30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS